Ethyl 4-(β-hydroxyphenethyl)-1-piperazincarboxylat | 486438-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Ethyl 4-(β-hydroxyphenethyl)-1-piperazincarboxylat
• 英文别名: Ethyl 4-(2-hydroxy-2-phenylethyl)piperazine-1-carboxylate
• CAS: 486438-97-5
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: DBOBVPUXSUIZDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 4-(β-hydroxyphenethyl)-1-piperazincarboxylat 在 氢氧化钾 、 氯化亚砜 作用下， 以 乙醇 、 二氯甲烷 、 苯 为溶剂， 生成 1-Methyl-4-(1-phenyl-2-piperazin-1-ylethyl)piperazine
  参考文献：
  名称：

  Structure−Activity Relationship of (1-Aryl-2-piperazinylethyl)piperazines:  Antagonists for the AGRP/Melanocortin Receptor Binding

  摘要：

  Agouti-related protein (AGRP) is an endogenous antagonist of the melanocortin action.(1) In the hypothalamus, melanocortin peptide agonists act as satiety-inducing factors that mediate their action through the melanocortin-4 receptor (MC4R) whereas AGRP is an opposing orexigenic agent. Novel inhibitors of the AGRP/MC4 binding based on (piperazinylethyl)piperazines were prepared, and their structure-activity relationship was established.

  DOI：

  10.1021/jm0255522
• 作为产物：
  描述：

  N-哌嗪甲酸乙酯 在 sodium tetrahydroborate 、 TEA 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 Ethyl 4-(β-hydroxyphenethyl)-1-piperazincarboxylat
  参考文献：
  名称：

  Structure−Activity Relationship of (1-Aryl-2-piperazinylethyl)piperazines:  Antagonists for the AGRP/Melanocortin Receptor Binding

  摘要：

  Agouti-related protein (AGRP) is an endogenous antagonist of the melanocortin action.(1) In the hypothalamus, melanocortin peptide agonists act as satiety-inducing factors that mediate their action through the melanocortin-4 receptor (MC4R) whereas AGRP is an opposing orexigenic agent. Novel inhibitors of the AGRP/MC4 binding based on (piperazinylethyl)piperazines were prepared, and their structure-activity relationship was established.

  DOI：

  10.1021/jm0255522

文献信息

• 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：EP0088903A2

  公开（公告）日：1983-09-21

  1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives of the general formula: or acid addition salts thereof, wherein W is -CH= or -N=; Y is -CH=CH-, -0-, -S-, -CH=N(O)p- (p is zero or 1) or -N(R)- (R is hydrogen or lower alkyl); X1, X2 and X3 are the same or different, and are each hydrogen, halogen, nitro, trifluoromethyl, cyano or lower alkylthio; Z is aryl or 5- or 6-membered aromatic heterocyclic ring (which may have a substituent or two or three substituents which may be the same or different, and the substituent may be halogen, lower alkyl, lower alkoxy, lower alkanoylamino, cyano, nitro, lower alkylthio, trifluoromethyl, sulfamoyl, di-lower alkylsulfamoyl, amino or di-lower alkylamino); -N A is 5- to 7-membered heterocyclic ring which may have nitrogen atom, oxygen atom, sulfur atom or unsaturated bond on the ring, and may be substituted by lower alkyl, lower alkoxycarbonyl, lower alkanoylamino, ethylenedioxy or ―(CH2)m―OR4 (R4 is hydrogen, lower alkyl or lower alkanoyl and m is 0, 1 or 2); R' and R2 are the same or different, and are eaah lower alkyl; R3 is lower alkyl, aralkyl, heteroaralkyl; and n is an integer 1 to 5. Such compounds are useful as antihypertensive agents and as therapeutic agents for cardiac and cerebral circulation disorders.

  通式为 1,4-二氢吡啶-3,5-二羧酸酯衍生物： 或其酸加成盐，其中 W 是-CH=或-N=；Y 是-CH=CH-、-0-、-S-、-CH=N(O)p-（p 是 0 或 1）或-N(R)-（R 是氢或低级烷基）；X1、X2 和 X3 相同或不同，并且各自是氢、卤素、硝基、三氟甲基、氰基或低级烷硫基；Z 是芳基或 5 或 6 元芳香杂环（可以有一个或两个或三个取代基，取代基可以是卤素、低级烷基、低级烷氧基、低级烷氨基、氰基、硝基、低级烷硫基、三氟甲基、氨基磺酰基、二低级烷基氨基磺酰基、氨基或二低级烷氨基）；-N A 是 5 至 7 元杂环，环上可有氮原子、氧原子、硫原子或不饱和键，可被低级烷基、低级烷氧羰基、低级烷酰氨基、亚乙基二氧基或 -(CH2)m-OR4 取代（R4 为氢、低级烷基或低级烷酰基，m 为 0、1 或 2）；R'和 R2 相同或不同，并且是 eaah 低级烷基；R3 是低级烷基、芳基、杂烷基；n 是 1 至 5 的整数。此类化合物可用作降压药和心脑循环障碍的治疗剂。
• Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
  申请人：TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION

  公开号：EP0157420A2

  公开（公告）日：1985-10-09

  According to the invention, there are provided novel amide derivatives and 5-lipoxygenase inhibitors containing the same as an effective ingredient. The above-mentioned compounds of the invention have been demonstrated to possess 5-lipoxygenase-inhibiting activities. These compounds can inhibit the production of leucotrienes such as LTC4 and LTD4 which are allergy-inducing factors by inhibiting the activity of 5-lipoxygenase. Accordingly, the amide derivatives can be used as 5-lipoxygenase inhibitors effective for allergic asthma, allergic rhinitis and the like.

  根据本发明，提供了新型酰胺衍生物和以酰胺衍生物为有效成分的 5-脂氧合酶抑制剂。 上述本发明化合物已被证实具有 5-脂氧合酶抑制活性。 这些化合物可以通过抑制 5-脂氧合酶的活性来抑制白三烯（如 LTC4 和 LTD4）的产生，而白三烯是过敏诱因。 因此，酰胺衍生物可用作 5-脂氧合酶抑制剂，对过敏性哮喘、过敏性鼻炎等有效。
• US4618607A
  申请人：——

  公开号：US4618607A

  公开（公告）日：1986-10-21
• US4673684A
  申请人：——

  公开号：US4673684A

  公开（公告）日：1987-06-16
• Moehrle; Azodi, Pharmazie, 2006, vol. 61, # 10, p. 815 - 822
  作者：Moehrle、Azodi

  DOI：——

  日期：——